Sheaff Brock Investment Advisors’s Endocyte, Inc. Common Stock ECYT Stock Holding History

Sheaff Brock Investment Advisors’s Portfolio ECYT Stock Details ECYT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-10,700	Closed	-$46K	–	594
2017 Q4	$46K	Buy	+10,700	New	+$51K	0.01%	518
2016 Q2	–	Sell	-13,400	Closed	-$42K	–	657
2016 Q1	$42K	Hold	13,400	–	–	0.01%	590
2015 Q4	$54K	Buy	+13,400	New	+$61.7K	0.01%	614

Other funds holding ECYT

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

VMI

VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

GTC

Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return

Sheaff Brock Investment Advisors's ECYT Position: Q1 2018 in Review

Sheaff Brock Investment Advisors sold out of Endocyte, Inc. Common Stock (ECYT) in Q1 2018, closing a stake of 10,700 shares — an estimated $46K sold.

Sheaff Brock Investment Advisors first reported a position in ECYT in Q4 2015 and held it in 3 quarters. The position peaked at $54K in Q4 2015. 89 funds tracked by Wall St. Rank hold ECYT as of Q1 2018.

Sheaff Brock Investment Advisors reported no remaining Endocyte, Inc. Common Stock position as of Q1 2018 after selling out during the quarter.
Sheaff Brock Investment Advisors sold 10,700 Endocyte, Inc. Common Stock shares in Q1 2018, an estimated $46K.
Sheaff Brock Investment Advisors first reported a position in Endocyte, Inc. Common Stock in Q4 2015 and held it in 3 quarters.
Sheaff Brock Investment Advisors's Endocyte, Inc. Common Stock position peaked at $54K in Q4 2015.
89 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q1 2018.

Based on Sheaff Brock Investment Advisors's 13F filing for Q1 2018, filed 3 May 2018.